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Nephronophthisis (NPHP) is a renal ciliopathy and an autosomal recessive cause of cystic 
kidney disease, renal fibrosis, and end-stage renal failure, affecting children and young 
adults. Molecular genetic studies have identified more than 20 genes underlying this 
disorder, whose protein products are all related to cilia, centrosome, or mitotic spindle 
function. In around 15% of cases, there are additional features of a ciliopathy syndrome, 
including retinal defects, liver fibrosis, skeletal abnormalities, and brain developmental 
disorders. Alongside, gene identification has arisen molecular mechanistic insights 
into the disease pathogenesis. The genetic causes of NPHP are discussed in terms of 
how they help us to define treatable disease pathways including the cyclic adenosine 
monophosphate pathway, the mTOR pathway, Hedgehog signaling pathways, and 
DNA damage response pathways. While the underlying pathology of the many types of 
NPHP remains similar, the defined disease mechanisms are diverse, and a personalized 
medicine approach for therapy in NPHP patients is likely to be required.
Keywords: ciliopathy, molecular genetics, nephronophthisis, cilia, centrosome, DNA damage, cyclic adenosine 
monophosphate, Joubert syndrome
iNTRODUCTiON
Nephronophthisis (NPHP) is an autosomal recessive inherited kidney disease, which leads to end-
stage renal disease (ESRD) typically within the first three decades of life (1). Traditionally, this 
disease was diagnosed using clinical and histological features. However, over recent years, many 
of the genetic causes underlying NPHP have been identified allowing both a precise molecular 
diagnosis to be made and some mechanistic insights into the underlying disease process. The 
known NPHP genes encode proteins that are almost all expressed in centrosomes and primary cilia. 
NPHP is therefore considered to be a ciliopathy disease (2), consistent with the fact that extrarenal 
manifestations, consistent will a ciliopathy syndrome, occur in around 20% of cases. Here we will 
review the clinical and histological features of the disease and its conventional classification before 
reviewing the underlying genetic causes and the ciliopathy syndromes associated with NPHP.
Based on the original histological descriptions, which included corticomedullary cysts, 
atrophy, and interstitial fibrosis, NPHP literally means disappearance or disintegration of 
nephrons (3). The clinical symptoms of NPHP, which reflect reduction in GFR and loss of distal 
tubular function (4), include polyuria, polydipsia, secondary enuresis, and growth retardation. 
Unfortunately, NPHP is associated with a progressive loss of kidney function and ESRD typically 
TAble 1 | Comparison of nephronophthisis (NPHP) with autosomal dominant 
tubulointerstitial kidney disease (ADTKD).
Diagnosis NPHP ADTKD
Inheritance Autosomal recessive Autosomal dominant
Gene(s) NPHP genes MUC1
UMOD
REN
SEC61A1
Extrarenal 
associations
Retinal degeneration Gout
Cerebellar vermis aplasia, gaze 
palsy, liver fibrosis, situs inversus, 
and skeletal defects
Radiological 
features
Small or normal-sized 
hyperechogenic kidneys and 
corticomedullary cysts (except 
infantile variant)
Small or normal sized 
hyperechogenic kidneys 
and corticomedullary cysts
Median age of 
end-stage renal 
disease
Usually under 30 years 16–80 years (MUC1)
30–50 years (UMOD)
FiGURe 1 | Typical histological features of nephronophthisis. (A) Light microscopy image. PAS stain demonstrates a globally sclerosed glomerulus and some 
periglomerular fibrosis. There is moderate interstitial fibrosis with chronic inflammation and thickening of tubular basement membranes. (b) Light microscopy image. 
H&E stain shows tubular atrophy with hyaline casts, moderate interstitial fibrosis, and patchy mononuclear inflammation. (C) Electron microscopy image. Tubular 
basement membrane demonstrates thickening and multilayering. Scale bar 2 µm.
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occurs before 30 years of age. Cases have historically been clas-
sified based on the age of onset of ESRD as infantile, juvenile, 
adolescent, and late onset. These are worth reviewing, although 
it is worth noting that a single genotype may present at a wide 
range of ages.
Juvenile NPHP is the classical form of NPHP and is charac-
terized by polyuria and polydipsia symptoms and often anemia 
in patients within the first decade of life. Progressive loss of 
kidney function leads to ESRD at a median age of 13 years (5).
Kidneys affected by NPHP are grossly normal or have a 
shrunken appearance, typical of ESRD. There may be corticome-
dullary cysts that are up to 1.5 cm in size. Cysts often develop in 
later stages of the disease. The renal ultrasound scan appearances 
may often display a loss of corticomedullary differentiation.
Where renal biopsies have been performed in NPHP patients, 
distinct histological features have been reported. The histologi-
cal changes can be divided into early or late stages of disease. 
In the early stages of the NPHP, there is interstitial fibrosis with 
sparse inflammation and lack of infiltration with neutrophils 
or monocytes. The tubules are tortuous and atrophic with seg-
mented tubular basement membrane thickening (6). The distal 
tubules have focal diverticulum like protrusions. The glomeruli 
are usually normal but there may be periglomerular fibrosis that 
can extend into the glomerular tuft leading to focal or global 
collapse of the tuft and obsolescence of the glomeruli (7, 8). In 
later stages of the disease, the tubules may demonstrate base-
ment membrane abnormalities with both atrophy and thicken-
ing. There often is cystic dilatation of the distal tubules, and the 
glomeruli may show collapse and severe periglomerular fibrosis 
(8, 9) (Figure  1). NPHP is not an immune mediated disease, 
and consequently there is no immune or complement deposi-
tion (6, 8). Electron microscopy may reveal tubular basement 
membrane duplication, thickening, and folding (6, 8). When 
examining clinical, pathological, and histological features of 
NPHP, it must be remembered that a separate disorder, known 
as medullary cystic kidney disease may share similar features. 
Medullary cystic kidney disease is an autosomal dominant 
condition, which is now classified under the term autosomal 
dominant tubulointerstitial kidney disease (ADTKD). Typical 
extrarenal manifestations include gout and anemia. A compari-
son of NPHP and ADTKD, alongside is given in Table 1 and has 
been discussed elsewhere (10).
Infantile NPHP is rare, but is noteworthy, due to its severe phe-
notype with ESRD typically occurring during the first year of life 
(7). There may be antenatal presentations with oligohydramnios 
and bilateral enlarged cystic kidneys. Infantile NPHP is usually 
caused by mutations in INVS (11) and NPHP3 (12) but has been 
reported for other genetic forms of NPHP such as NEK8 (13) and 
CEP83 (14). The macroscopic and histological kidney phenotype 
is markedly different from other varieties of NPHP, with enlarged 
cystic kidneys, as opposed to micro and small corticomedullary 
cysts. Histologically, infantile NPHP lacks the tubular basement 
membrane changes seen in other NPHP phenotypes and may 
resemble autosomal recessive polycystic kidney disease. There 
may also be severe cardiac anomalies including situs inversus and 
ventricular septal defects (15).
The adolescent form of NPHP was originally described in a 
large Venezuelan pedigree (16). Biallelic mutations in NPHP3 
were found in this family, resulting in ESRD at a median age 
of 19  years (16). It is now known that NPHP3 mutations may 
lead to a broad range of phenotypes including perinatal lethal 
Meckel–Gruber syndrome and infantile presentations. The 
term “adolescent NPHP” is thus somewhat arbitrary and merely 
extends the phenotypic spectrum from juvenile NPHP.
TAble 2 | Extrarenal manifestations of nephronophthisis (NPHP) and their 
associated syndromes.
extrarenal manifestation 
associated with NPHP
Syndrome
Retinitis pigmentosa/retinal dystrophy Senior–Løken syndrome
Alström syndrome
Arima syndrome
Oculomotor apraxia Cogan syndrome
Nystagmus Joubert syndrome and related disorders
Ocular coloboma Joubert syndrome and related disorders
Posterior encephalocele Meckel–Gruber syndrome
Abnormal respiratory pattern Joubert syndrome and related disorders
Cerebellar vermis aplasia/hypoplasia Joubert syndrome and related disorders
Liver fibrosis Joubert syndrome and related disorders
Meckel–Gruber syndrome
Arima syndrome
Postaxial polydactyly Bardet–Biedl syndrome
Joubert syndrome and related disorders
Skeletal dysplasia Ellis–van Creveld syndrome
Sensenbrenner syndrome
Jeune syndrome
Mainzer–Saldino syndrome
Situs inversus/cardiac malformation Infantile NPHP
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A number of case reports have highlighted the fact that 
NPHP may first present later in life. Georges et  al. reported 
three (genetically unsolved) families with retinal dystrophy, 
NPHP on renal biopsy and slowly progressive renal failure and 
ESRD between the ages of 42 and 56 years (17). In another fam-
ily with a homozygous NPHP1 deletion (18) ESRD was reported 
in three patients between 27 and 43 years of age. These cases 
of NPHP extend the age of ESRD from birth to up to the sixth 
decade of life.
AN APPROACH TO THe CliNiCAl 
DiAGNOSiS OF NPHP
Clinical recognition of NPHP is important, and the renal and 
extrarenal features of a ciliopathy syndrome (discussed below) 
may allow a clinical diagnosis to be made. NPHP occurs in isola-
tion in around 80% of cases and is associated with a variety of 
other ciliopathy phenotypes in 20% of cases. A detailed review 
with specific emphasis on the family history and extrarenal 
features known to be associated with NPHP is therefore an 
essential prerequisite to an exact diagnosis. NPHP is charac-
terized by a urinary concentrating defect early on in life that 
leads to polyuria and polydipsia. The onset of the disease may 
be easily missed, as there is typically no severe hypertension, 
minimal or no proteinuria, and a bland urine sediment. Clinical 
spectrums of disease are wide and widening. Besides extensive 
investigations of renal function, clinical phenotyping should 
also encompass a full neurological screening to assess for cer-
ebellar signs and fundoscopy to assess for retinal degeneration. 
A formal ophthalmological examination is advised. The role of 
renal biopsy in diagnosing NPHP is contentious and should be 
limited to cases where a tissue diagnosis will serve to distinguish 
it from other differential diagnoses. In most cases, a histopatho-
logical diagnosis should be superseded by a molecular genetic 
diagnostic approach, because genetic screening allows for early 
diagnosis and prevents complications of renal biopsy. NPHP1 
mutations and deletions are the most frequent genetic cause 
of NPHP and may be screened for using standard PCR assays 
(19). Given the large numbers of other NPHP genes involved 
multiplex PCR (20), targeted exon capture or whole-exome 
sequencing approaches are recommended (21).
eXTRAReNAl MANiFeSTATiONS  
OF NPHP
There are several important additional phenotypes that may be 
associated with NPHP (Table  2). These multisystem features 
are consistent with the fact that NPHP is a ciliopathy and may 
affect retina, brain, liver, and other tissues either by prenatal-
onset dysplasia or by postnatal organ degeneration and fibrosis. 
Extrarenal manifestations are seen in ~20% of cases (22). In a 
recent study where 89 patients with NPHP mutations were ana-
lyzed, NPHP1 mutations were the most common genetic cause 
and gave rise to typical renal presentations. These included 
increased echogenicity of the kidney and loss of corticomedul-
lary differentiation, with cystic kidney disease presenting later 
in the disease course (median age 12.3  years) and ESRD at a 
median age of 12.8  years (23). Extrarenal manifestations of 
NPHP1 mutations were seen more frequently than expected, 
with 8% presenting with liver symptoms, 19% having develop-
mental delay and 7% epilepsy and seizures (23). The important 
syndromes associated with NPHP are briefly described below.
NPHP with Retinitis Pigmentosa  
(Senior–løken Syndrome)
Retinal dysplasia and degeneration is seen in 10–15% of patients 
with NPHP and may lead to an early and severe visual loss 
resembling Leber congenital amaurosis (LCA) (24, 25). Later 
onset forms present initially with night blindness, which then 
progresses to visual loss.
Cerebellar vermis Aplasia/Hypoplasia  
with NPHP (Joubert Syndrome)
Joubert syndrome is a developmental disorder characterized by 
cerebellar vermis hypoplasia (26). Brain imaging (MRI) reveals 
the typical sign known as the “molar tooth sign.” Clinical fea-
tures include hypotonia, cerebellar ataxia, neonatal tachypnea, 
and developmental delay. There may also be ocular coloboma, 
polydactyly, and hepatic fibrosis. NPHP is found in up to 30% 
of Joubert syndrome patients (27–29). Large cohorts of Joubert 
syndrome patients have been described, allowing some geno-
type/phenotype correlations to be made in the more frequent 
genetic causes. Mutations in TMEM67 in Joubert syndrome are 
the most frequently associated with kidney disease, whereas 
mutations in CEP290 were most likely to give retinal, renal, and 
brain phenotypes (28). In a recent cohort analysis of 97 patients 
with Joubert syndrome, renal phenotypes were detect in 30% of 
cases and was commonly associated with NPHP genes including 
CEP290, TMEM67, and AHI1 (29). In this study, renal pheno-
types in Joubert syndrome extended beyond classical NPHP 
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and included an overlapping phenotype resembling autosomal 
recessive polycystic kidney disease and NPHP (mimicking 
infantile NPHP), unilateral multicystic dysplastic kidney and 
indeterminate cystic kidney disease phenotypes (29).
Oculomotor Apraxia (OMA) Type Cogan
Oculomotor apraxia type Cogan is an eye movement disorder. 
It is characterized by abnormal horizontal eye movements that 
include nystagmus and difficulty with saccades (smooth visual 
pursuits) and has been associated with NPHP (2, 30). OMA may 
be a mild form of Joubert syndrome, as cerebellar vermis aplasia 
has been described in this condition (31).
Perinatal lethality (Meckel–Gruber 
Syndrome)
Meckel–Gruber syndrome is characterized by occipital ence-
phalocele, polydactyly, bile ductal proliferation, and cystic 
kid ney dysplasia. Typically, the condition is perinatally lethal. 
The syndrome is associated with severe biallelic mutations 
in NPHP genes that include NPHP3, CEP290, and RPGRIP1L 
(1, 32–35).
Skeletal Defects [Jeune Syndrome  
(JS), Sensenbrenner Syndrome,  
and Saldino-Mainzer Syndrome]
Various skeletal defects have been reported in association 
with NPHP. These include cone-shaped epiphyses (16, 36), 
shortening of limbs, and ribs, scoliosis, polydactyly, brachy-
dactyly, and craniosynostosis. Mutations are in genes encoding 
intraflagellar transport (IFT) proteins including TTC21B and 
WDR19 (37–41).
episodic Hyperpnea (Joubert Syndrome)
The original report of Joubert syndrome (42) described episodes 
of fast breathing followed by a period of apnea. This feature is 
demonstrable only when the patient is awake. Abnormal respira-
tory pattern is not a consistent feature of Joubert syndrome and 
the reported incidence varies (44–71%) (43).
Anosmia As an extrarenal Manifestation  
of Renal Ciliopathies
Several renal ciliopathy syndromes have been associated with 
anosmia, secondary to olfactory cilia defects. This has been stud-
ied in most detail in Bardet–Biedl syndrome (BBS) (44, 45) but 
has been reported in patients with LCA secondary to mutations 
in CEP290 and in a murine model of Cep290 (46). Such data also 
suggest a link between ciliary defects in the olfactory neurons 
and kidney disease. Indeed, proteins that mediate olfactory-like 
chemosensory signaling pathways were found expressed in the 
renal tissue (47), including adenylate cyclase III, which is local-
ized to the primary cilium (48). These pathways may be vital in 
tubuloglomerular feedback and blood pressure control. There is 
a real need now to assess patients with renal ciliopathies/NPHP 
(and indeed corresponding murine models) for defects in smell 
and to determine a role for olfactory-like signaling within the 
kidney.
KNOwN GeNeTiC CAUSeS OF NPHP
There are now more than 20 genes that if mutated may lead to 
NPHP (Table 3). It is worth reviewing these genetic causes as 
they all point toward some mechanistic insights into the patho-
genesis of NPHP. Finding commonality among the genetic 
causes relies on a connection to the centrosome/basal body/
primary cilium, although this may not be true for every genetic 
cause.
The most common genetic cause of NPHP is mutations in 
NPHP1, which account for around 20% of cases. The most com-
mon NPHP1 gene defect is a large homozygous deletion affecting 
the whole gene (49, 79). Each of the remaining NPHP genes 
probably accounts for 1% or less of all cases of NPHP, meaning 
that around two-thirds of cases remain genetically unsolved (2). It 
is noteworthy that mutations in a single NPHP gene may give an 
extremely wide spectrum of clinical phenotypes that may include 
isolated NPHP, NPHP with additional features, such as Senior–
Løken syndrome and Joubert syndrome and severe neonatal 
lethal forms, such as of Meckel–Gruber syndrome. Linkage stud-
ies and painstaking mapping approaches led to the identification 
of NPHP1 in 1997 (49). Similar approaches for the next decade 
(sometimes combined with candidate gene screens) allowed the 
discovery of eight genes (at a rate of around one new gene per 
year). Since 2010, next-generation sequencing approaches have 
been utilized (80) allowing the detection of NPHP genes at a 
much faster rate.
NPHP1
NPHP1 encodes nephrocystin-1 (alias nephrocystin). It was 
shown to interact with p130cas, tensin, filamin, and focal adhe-
sion kinase 2, all molecules involved in cell–cell adhesion and 
cell signaling (81–83). In the primary cilium, nephrocystin-1 
interacts with nephrocystin-4 and RPGRIP1L at the transition 
zone and links it to inversin (77).
INVS
INVS causes ESRD in the first 2 years of life and presents typically 
as an infantile form of NPHP as described earlier. The frequency 
of INVS mutations has been reported to be as high as 78% in the 
group of patients reaching ESRD before 2 years of age (12). The 
kidney size in INVS is often enlarged unlike most other forms 
of NPHP in which the kidneys are normal in size or shrunken 
(12). The distribution of cysts is corticomedullary and is more 
reminiscent of autosomal recessive polycystic kidney disease, 
given the kidneys can be massively enlarged.
Inversin, the gene product of INVS interacts with nephrocystin-1 
and nephrocystin-3 and plays a vital role in intercellular adhe-
sion (84). It localizes to the cilium and serves as a switch between 
the canonical and non-canonical Wnt pathway (85). Otto et al. 
established a link between cystogenesis and the primary cilia 
in humans disease during the study of this disease in 2003 (11) 
establishing this as a landmark paper in the study of NPHP and 
ciliopathies. Inversin is also plays a role in planar cell polarity 
(PCP) processes, discussed below. Loss of inversin leads to 
abnormal mitotic spindle orientation (86), which may drive 
cystogenesis.
TAble 3 | Genetic classification of NPHP, its related disorders and the key insights obtained.
HGNC gene 
symbol
NPHP 
type
Disorders associated 
with mutations
Key insights Reference
NPHP1 NPHP1 NPHP/SLSN/JBTS Localizes to microtubular organizing center, cell–cell junction, and ciliary transition  
zone protein
(49, 50)
INVS NPHP2 NPHP/SLSN (including 
infantile NPHP) situs 
inversus
Localizes to primary cilium (inversin compartment). Protein possesses nuclear localization 
signals suggesting role in nucleus. Role in Wnt signaling and left–right determination
(11)
NPHP3 NPHP3 NPHP/SLSN/MKS 
(including infantile NPHP)
NPHP3 interacts with ANKS6, INVS, and NEK8 in a ciliary protein complex. Murine model 
Pcy has a hypomorphic Nphp3 allele and has been utilized in pharmacological studies
(16, 51)
NPHP4 NPHP4 NPHP/SLSN Localizes to primary cilia and cell–cell junctions. Role in transition zone of cilia (52)
IQCB1 NPHP5 SLSN/LCA Localizes to connecting cilium of photoreceptor cells and to primary cilia of renal  
tubular cells
(53)
CEP290 NPHP6 JBTS/BBS/MKS/LCA/
SLSN
Centrosomal protein localizes to mother and daughter centrioles and to transition zone. 
Protein contains a nuclear localization signal and localizes to nucleus
(33, 54, 55)
GLIS2 NPHP7 NPHP Localizes to nucleus and primary cilia. Increase in apoptosis and fibrosis in murine  
model Glis2
(56)
RPGRIP1L NPHP8 JBTS/MKS Ciliary transition zone protein and facilitates vesicular docking of ciliary proteins (1, 57)
NEK8 NPHP9 NPHP (including infantile 
NPHP)
Localizes to primary cilium (inversin compartment). Links cilia and cell cycle defects  
in NPHP
(13)
SDCCAG8 NPHP10 SLSN/BBS Localizes to centrosomes and cell–cell junctions. Localized in nucleus and implicated  
in DNA damage repair pathways
(58, 59)
TMEM67 NPHP11 NPHP/MKS/JBTS/
COACH syndrome
Localizes to transition zone and to plasma membrane. Required for ciliogenesis and 
centriole migration
(60–62)
TTC21B NPHP12 NPHP/JBTS Intraflagellar transport (IFT) protein involved in retrograde transport. Localizes to cilia. (37)
WDR19 NPHP13 NPHP/JBTS IFT protein, involved in retrograde transport and ciliogenesis (38, 39)
ZNF423 NPHP14 JBTS Nuclear and centrosomal protein and role in DNA repair signaling. Znf423−/− mice  
exhibit cerebellar defects
(63, 64)
CEP164 NPHP15 NPHP/SLSN/JBTS Centrosomal protein and role in DNA repair signaling. Plays a critical role in G2/M 
checkpoint and nuclear division. Localizes to nuclear foci
(63)
ANKS6 NPHP16 NPHP Functional module with inversin and nephrocystin-3 (65, 66)
IFT172 NPHP17 NPHP/Jeune/Mainzer–
Saldino syndrome
IFT protein (IFT-B module), defects affect both anterograde and retrograde IFT (67)
CEP83 NPHP18 NPHP (including infantile 
NPHP)
Distal appendage protein of centriole, required for membrane contact during  
ciliogenesisis
(14, 68)
DCDC2 NPHP19 NPHP/liver fibrosis Ciliary and mitotic spindle protein, mutations disrupt Wnt signaling (69)
MAPKBP1 NPHP20 NPHP Mitotic spindle pole protein (70)
AHI1 JBTS3 NPHP/JBTS Localized to basal bodies and cell–cell junctions. Important for cerebellar development (71–74)
CC2D2A JBTS/COACH  
syndrome/MKS
Transition zone protein, regulates cilia-directed cargo vesicle docking (75)
XPNPEP3 NPHPL1 NPHP Mitochondrial defect linking ciliopathies with mitochondria and potential novel pathways  
of disease
(76)
ATXN10 NPHP/spinocerebellar 
ataxia
Interacts with IQCB1. Nuclear and cytoplasmic localization (77)
SLC41A1 NPHP-like/primary ciliary 
dyskinesia
Renal magnesium transporter defect. Ciliary localization not confirmed (78)
BBS, Bardet–Biedl syndrome; COACH, cerebellar vermis hypo/aplasia, oligophrenia (mental retardation), ataxia, ocular coloboma, and hepatic fibrosis; JBTS, Joubert syndrome; 
LCA, Leber congenital amaurosis; MKS, Meckel syndrome; NPHP, nephronophthisis; SLNS, Senior–Løken syndrome.
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NPHP3
Omran et  al. first described mutations in NPHP3 in a large 
Venezuelan family in 2000 (87). It is characterized by NPHP, situs 
inversus, and structural heart defects. Hoff et al. uncovered a link 
between nephrocystin-3, inversin, and NEK8 (65) in a report on 
the role of ANKS6, linking the above proteins at the proximal part 
of the primary cilium known as the inversin compartment. This 
may explain the overlap seen in the phenotype of patients with 
mutation in INVS, NPHP3, and NEK8.
6Srivastava et al. Genetics of NPHP
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NPHP4
NPHP4 was identified by homozygosity mapping and genome 
wide linkage analysis by Mollet et  al. in patients with NPHP 
who did not have mutations in the NPHP1, 2, and 3 genes. 
Nephrocystin-4 localizes to the primary cilia and cortical actin 
cytoskeleton in the polarized cells. In dividing cells, it localizes to 
the centrosomes. It has been shown to interact with p130 (Cas), 
tensin, and filamin (88).
IQCB1
Patients with IQCB1 mutations are characterized by the pres-
ence of retinitis pigmentosa with NPHP (renal–retinal or 
Senior–Løken syndrome). In a study investigating the asso-
ciation of retinitis pigmentosa with NPHP, Otto et  al. found 
a novel gene IQCB1 that associates with retinitis pigmentosa 
GTPase regulator (RPGR) and calmodulin in the retinal con-
necting cilia, an analogous structure of the ciliary transition 
zone (53).
CEP290
Mutations in the CEP290 gene underlie NPHP6 and are 
the leading cause of Joubert syndrome and related diseases, 
a cerebello–retinal–renal syndrome. The association of CEP290 
with NPHP was established in 2006 in a cohort of families 
with Joubert syndrome, Senior–Løken syndrome, and NPHP 
(54, 55). CEP290 was found to interact with the transcription 
factor ATF4, which is involved in cyclic adenosine mono-
phosphate (cAMP) mediated cyst formation (54). CEP290 
mutations are the most common inherited cause of retinal 
degeneration (LCA). Mutations in CEP290 may also cause BBS 
phenotypes (89).
TMEM67 (33, 90) and CC2D2A (91, 92) are both interacting 
partners of CEP290 and can cause severe ciliopathy phenotypes 
including Meckel–Gruber syndrome and Joubert syndrome. 
There is emerging evidence of the role of CEP290 in ciliogenesis 
(93), cell signaling (94, 95), DNA damage response (DDR) (96), 
and consequently renal cystogenesis (97).
GLIS2
In 2007, Attanasio et al. reported a mutation in GLIS2 as a novel 
cause for NPHP. The loss of this transcription factor leads to 
increased fibrosis and apoptosis (56). In a recent paper, GLIS2 loss 
has been found to increase cell senescence. Kif3a null mice show 
increased cyst formation due to unrestrained proliferation, desta-
bilization of p53 and increased DNA damage. This is partially 
rescued by ablation of GLIS2 and pharmacological stabilization 
of p53 (98).
RPGRIP1L
Arts et  al. identified mutations in RPGRIP1L as causative for 
Joubert syndrome in three families in 2007. This protein localizes 
to the basal body and interacts with NPHP4 (57).
NEK8
Otto et  al. identified NEK8 as the causative gene for Joubert 
syndrome after observing that the jck mouse harbors a mutation 
in the highly conserved RCC1 domain of Nek8. They performed 
a mutational analysis of a worldwide cohort of patients and 
established the pathogenic role of NEK8 mutations in humans 
(13). More recently, NEK8 loss was implicated in increased DNA 
damage in the pathogenesis of NPHP (99). This established one 
of the first associations between the role DDR and cystic kidney 
disease. Grampa et  al. have recently described the association 
of NEK8 with deregulation of the Hippo pathway and its role in 
severe syndromic renal cystic dysplasia (100). Al-Hamed et al. 
described a stillborn fetus with cystic kidneys, oligohydramnios, 
CVA and bilateral bowing of the femur secondary to NEK8 
mutation (101).
SDCCAG8
SDCCAG8 was the first NPHP gene to be identified using next-
generation sequencing approaches (58). Patients with mutations 
in this gene were diagnosed with Senior–Løken syndrome, but 
may also have features suggestive of BBS (102). The encoded 
protein SDCCAG8 localizes to centrioles and directly inter-
acts with the ciliopathy-associated protein OFD1. A recently 
described murine model of SDCCAG8 has implicated elevated 
levels of DDR signaling as a potential mechanism of kidney 
disease (59).
TMEM67
Otto et  al. screened a cohort of 62 patients with NPHP and 
liver fibrosis and found hypomorphic mutations in TMEM67 
in 8% of the patients (61). TMEM67 has been implicated in the 
pathogenesis of Meckel–Gruber syndrome, Joubert syndrome, 
and COACH syndrome (cerebellar vermis hypo/aplasia, 
oligophrenia, congenital ataxia, coloboma and congenital 
hepatic fibrosis) (33, 34). Liver fibrosis is a frequent feature of 
TMEM67 mutations, and any patient with NPHP along with 
liver involvement should have tests for mutations in TMEM67. 
In a cohort of 100 patients with Joubert syndrome, mutations 
in TMEM67 were most frequently associated with kidney 
disease (28).
TTC21B
Davis et al. reported the association of TTC21B mutations with 
both isolated NPHP and JS (37). TTC21B encodes the retrograde 
IFT protein IFT139, which has been shown to regulate Hedgehog 
signaling (103).
WDR19
WDR19 mutations have been reported in patients with cili-
opathy syndromes including Sensenbrenner syndrome, Joubert 
syndrome, Senior–Løken syndrome, and isolated NPHP (38, 41, 
104). WDR19 encodes for IFT144, a protein that participates in 
retrograde IFT and is important for ciliogenesis.
ZNF423
ZNF423 mutations have shown to cause Joubert syndrome with 
NPHP (63). The encoded protein ZNF423 is a nuclear protein 
which functions as a DNA-binding transcription factor and inter-
acts with DDR protein PARP1 [poly (ADP-ribose) polymerase 1] 
and also CEP290 (63).
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CEP164
Mutations in CEP164 may cause NPHP and related ciliopathy 
syndromes including Senior–Løken syndrome (63). The CEP164 
protein is a regulator of ciliogenesis and is essential for the forma-
tion of the distal appendage of the centriole (105). Loss of CEP164 
induces DNA damage (63).
ANKS6
ANKS6 mutations lead to NPHP. ANKS6 localizes to the inversin 
compartment and links the NPHP proteins NPHP2, NPHP3, 
and NPHP9 to NEK8. This functional role of ANKS6 in an 
NPHP module may explain the phenotypic overlap that includes 
abnormalities in heart and liver, seen in the patients carrying 
individual mutations in these genes (65, 66).
IFT172
Intraflagellar transport is vital in maintaining the cilium and 
in executing its functions. IFT-A module has six components, 
and mutations in genes encoding these proteins have all been 
associated with ciliopathy diseases. IFT-B has 14 components. 
Halbritter et  al. established the first link between IFT-B com-
ponent IFT172 and skeletal ciliopathies. Some patients in this 
cohort had NPHP (67). Mutations in IFT172 may also cause BBS 
syndrome (106).
CEP83
CEP83 mutations have recently been described to cause infantile 
NPHP (14). CEP83 encodes a centriolar distal appendage pro-
tein, CEP83. In the seven families so far described, the NPHP 
phenotype was early-onset (juvenile), and in some was also 
associated with hydrocephalus and learning difficulties (14).
DCDC2
Schueler et al. reported a novel mutation in the gene DCDC2, in 
patients presenting with an NPHP and hepatic fibrosis phenotype 
(69). DCDC2 localizes to the ciliary axoneme and the mitotic 
spindles. DCDC2 knockdown inhibits ciliogenesis. It interacts 
with DVL, and DCDC2 knockdown leads to defects in Wnt 
signaling and may contribute to the liver fibrosis (69).
MAPKBP1
Macia et  al. have recently described a novel gene, MAPKBP1, 
in five families with eight individuals presenting with juvenile 
or late-onset NPHP with massive fibrosis. This gene encodes 
MAPKBP1, a scaffolding protein for JNK signaling. Interestingly, 
this protein does not localize to the primary cilium instead it 
localizes to the mitotic spindle pole. The authors also report 
increased DDR signaling in murine fibroblasts upon knockdown 
of Mapkbp1 (70).
AHI1
Mutations in AHI1 were initially described in patients with 
Joubert syndrome and no kidney involvement (71, 72). However, 
AHI1 mutations may cause NPHP phenotypes (73) and may 
cause multicystic dysplastic kidneys also (29). AHI1 is localized 
to the basal body and cell–cell junctions (74).
CC2D2A
Mutations in CC2D2A have been reported to cause Joubert 
syndrome with and without cystic kidney disease (92). CC2D2A 
is localized to the basal body and colocalizes with CEP290 (92). 
Mutations in CC2D2A may also cause antenatal cystic kidney 
disease phenotypes and severe brain phenotypes (typical of 
Meckel–Gruber syndrome) leading to fetal death (101).
eviDeNCe OF OliGOGeNiCiTY  
AND TRiAlleliSM iN NPHP
Alongside the novel findings relating to gene discovery in NPHP 
has been the continued theme of wide phenotypic variability, 
especially in extrarenal manifestations. The type of mutation 
may influence the phenotype in certain circumstances. Examples 
include CC2D2A (107, 108) and TMEM67 (109) where two 
truncating mutations tend to lead to more severe phenotypes 
than missense mutations. With the now frequent sequencing of 
NPHP cohorts (110, 111) and the use of high-throughput genetic 
sequencing platforms (112), a few findings of oligogenicity and 
triallelism within NPHP have been reported; however, these are 
controversial as these findings are anecdotal. As an example, a het-
erozygous AHI1 mutation when inherited with biallelic NPHP1 
mutations seems to lead to a more severe brain phenotype (111). 
Thus, a concept of mutation burden seems relevant to NPHP, 
and like BBS (113) it will be important that these variants are 
reported and that they are assessed in terms of their pathogenic-
ity. Interestingly, NPHP1 mutations and copy number variants, as 
well as causing NPHP and Joubert syndrome, may also contribute 
to the mutational burden of BBS (114, 115). More recent next-
generation sequencing data studying Joubert syndrome suggest 
that rare disease variants are frequently found in addition to 
the causal biallelic variants. Typically, over one-third of affected 
individuals carry rare disease variants in addition to the causal 
mutations but importantly they did not correlate with disease 
severity (116). This study also found no evidence or support 
for triallelism. Discordant phenotypes between affected siblings 
were observed in 60% of subjects who shared causal mutations, 
suggesting that modifier alleles are important but elusive (116). 
Therefore, using third alleles and other NPHP gene variants of 
uncertain significance to determine additional phenotypes and 
disease severity and inform genetic counseling is not presently 
advised, or should only be done with the utmost care.
PATHOGeNeSiS OF NPHP
There are various theories behind the pathogenesis of the NPHP 
disease process. The very early hypotheses were based entirely 
on the histopathological description of the disease and led to the 
widespread belief that this disease was caused by some unknown 
nephrotoxic agent or an enzyme defect (8). The frequent finding 
of tubular basement membrane thickening led to a basement 
membrane hypothesis for the pathogenesis of NPHP. It was 
observed that nephrocystin-1, the protein product of NPHP1 had 
a high degree of sequence conservation with CRK (a focal adhe-
sion protein) (117), contained an SH3 domain and interacted 
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with other proteins including p130Cas and ACK1 (49, 118). 
Nephrocystin-1 was shown to localize to adherens junctions and 
focal adhesions. This supported a hypothesis that nephrocystin-1 
has an important role in the maintenance of the tubular epithe-
lium and that abnormal cell–cell and cell–matrix interactions 
were the underlying defect in NPHP. Many years later, the debate 
of the initial pathogenic defect in NPHP continues, with the 
focus on NPHP as a ciliopathy (119). This hypothesis is strongly 
supported by multiple gene discoveries in NPHP with nearly all 
the affected genes coding for the components of the cilia, basal 
body or centrosome. Defects in primary cilia associated with 
cystic kidney disease were initially noted in Ift88 mutant mice 
(120). This link between NPHP and cilia was confirmed in human 
disease established after the discovery that INVS mutations cause 
infantile NPHP and that the encoded protein inversin interacts 
with nephrocystin-1 and β-tubulin, colocalizing with them to the 
primary cilia of renal tubular cells (11). There is now almost uni-
versal agreement that the primary cilia are at the center of the dis-
ease process especially in terms of cystogenesis although it should 
not be forgotten that nephrocystins may have multiple subcellular 
localizations (54) and may play different roles in different tissues 
(1). There is an interesting overlap with the localization and func-
tion of NPHP genes and other “cystogenes” such as PKD1, PKD2, 
and the many other inherited causes of cystic kidney disease. The 
functional role of primary cilia in the human nephron is not fully 
understood. It was initially thought that the encoded proteins 
from PKD1 and PKD2, namely, polycystin-1 and polycystin-2, 
were able to sense luminal flow of urine, and ciliary deflection 
stimulated calcium entry into the cell via the polycystin proteins 
leading to downstream signaling cascades (121). However, more 
recent studies have challenged this hypothesis (122, 123).
A COMPARiSON OF NPHP AND ADPKD 
PATHOPHYSiOlOGY
A detailed discussion of the underlying pathophysiology of 
ADPKD has been recently published and is beyond the scope of 
this review (124). It is worth highlighting, however, that disease 
pathways in ADPKD involve cAMP, ciliary dysfunction, PCP and 
centrosome number as well as many others (124). Thus, these 
mechanisms of disease are shared with those of NPHP. Indeed, 
the development of tolvaptan, a vasopressin V2 receptor (V2R) 
antagonist for the use in patients with ADPKD was pioneered 
in murine models of NPHP (51). However, fluid secretion and 
proliferation seems less prominent in NPHP, while fibrosis and 
scarring are more prominent pathological features. The pairing 
of potential disease mechanisms in NPHP with targeted thera-
peutics will hopefully allow better treatments for NPHP in the 
near future (125).
OTHeR KeY MOleCUlAR PATHwAYS 
iMPliCATeD iN NPHP
Planar Cell Polarity
Planar cell polarity is an evolutionary conserved mechanism by 
which cells maintain their orientation in a plane perpendicular 
to the apical-basal polarity of a cell layer. This is achieved by the 
correct alignment and orientation of cell division, orchestrated 
by the mitotic spindle and centrosomes. The maintenance of 
tubular diameter is dependent upon PCP signaling, and when 
this is defective, tubular dilatation rather than elongation is 
thought to contribute to cystogenesis (126, 127). Non-canonical 
Wnt signaling is vital for these signaling events and mutations 
in INVS are thought to lead to defective regulation of this 
pathway (84, 85). Mutations in DCDC2, leading to NPHP type 
19 have also been implicated in this pathway, lending weight 
to this mechanism of cytogenesis and NPHP. Loss of Dcdc2 in 
IMCD3 cells led to an activation of Wnt signaling, leading to a 
loss of cilia, which was amenable to treatment with Wnt inhibi-
tor treatment (69). Other connections to the Wnt pathway in 
NPHP includes CEP164 which interacts with disheveled protein 
3 (DVL3) (63). The disheveled protein is a key component of 
the Wnt pathway, and part of the switch between canonical and 
non-canonical Wnt signaling. Defective Wnt signaling has also 
been demonstrated in murine models of Joubert syndrome. 
Ahi1 mutant mice showed defect in cerebellar midline fusion in 
sites of reduced Wnt activity (128) while renal tissues from the 
same mice demonstrated abnormal Wnt signaling in late stages 
of NPHP (129). A murine gene trap model of Cep290 similarly 
showed Wnt pathway changes (reduced Tcf1 protein) only at 
later stages of the disease (murine kidney tissue aged 1  year) 
implicating this pathway in renal fibrosis (95). The relation-
ship between Wnt signaling and cystic kidney disease has been 
recently reviewed (130).
cAMP Signaling
A huge amount of data have demonstrated the key role of 
elevated cAMP in mural epithelial cell proliferation and fluid 
secretion, which are the main drivers of cyst formation in poly-
cystic kidney disease (131). However, some lines of evidence 
suggest that high cAMP levels are also implicated in junctional 
and polarity defects in NPHP. Levels of cAMP were found to 
be elevated in Nphp3-, Nphp6-, and Nphp8-stable knockdown 
mIMCD3 lines. When these cells were examined in a 3D sphe-
roid culture system, they formed abnormal spheroids with no 
lumen and/or misaligned nuclei. Treatment with octreotide, an 
inhibitor of cAMP production, could rescue these structural 
abnormalities, linking high cAMP levels to cell polarity defects 
(132). Furthermore, it was shown that treatment with the 
cAMP analog 8-bromo-cAMP resulted in a dose-dependent 
loss of SDCCAG8 (NPHP10) protein in cell–cell junctions of 
the renal epithelial cell line MDCK-II, highlighting the poten-
tial role of high cAMP in perturbation of tissue architecture 
(58). Importantly, elevated cAMP levels and expression levels 
of the cAMP-dependent gene Aquaporin-2 were found in the 
renal tissue of Pcy mice that carry a missense mutation in 
Nphp3 (51).
mTOR Pathway
Increased mTOR (mechanistic target of rapamycin) activity was 
found in cystic kidney (133, 134) and in particular in cyst-lining 
epithelium (135) of several NPHP mouse models. mTOR is an 
atypical serine/threonine kinase that, by integrating a variety of 
9Srivastava et al. Genetics of NPHP
Frontiers in Pediatrics | www.frontiersin.org January 2018 | Volume 5 | Article 287
signals from nutrients and growth factors, regulates cell growth 
and proliferation.
The detailed subcellular localization of mTOR pathway 
components is not clear but it has been showed that primary 
cilium is important for the regulation of mTOR pathway 
(136, 137). It has been proposed that the flow-dependent bend-
ing of primary cilium represents a mechanosensory signal that 
controls cell size through the regulation of mTOR activity (137). 
Consequently, cilia abnormalities may ultimately result in cell 
growth deregulation, which could be potentially critical for the 
tubular geometry of the kidney.
THe ROle OF CiliA iN SONiC 
HeDGeHOG SiGNAliNG AND  
Cell CYCle
The Hedgehog (Hh) signaling pathway is a key developmental 
pathway and was first discovered in Drosophila (138). There 
are three mammalian Hh homologs, Desert, Indian, and Sonic. 
The sonic Hh (Shh) pathway is essential for development (139), 
patterning, organogenesis, and cell signaling (140). It acts as a 
morphogen and a mitogen and dysregulation of the pathway 
can lead to severe developmental defects and can give rise to 
various cancers (141). Shh signaling is intimately related to the 
primary cilium (141). The receptor Patched (Ptch1) is 12-pass 
transmembrane protein localized to the primary cilium. It has 
an inhibitory effect on the translocation of Smoothened (Smo, 
a G-protein-coupled-like receptor). The secreted ligand Shh binds 
to Ptch1 and triggers internalization of Ptch1 into endocytic 
vesicles. This allows the translocation of Smo into the primary 
cilium and its stepwise activation (142). Downstream effector 
Glioma proteins (Gli2,3) remain in a neutral state under the 
effect of suppressor of fused and by sequential phosphorylation 
by protein kinase A, glycogen synthase kinase 3β, and casein 
kinase 1, they undergo proteolytic conversion to their repressor 
form. Smo, when enriched in the primary cilium and activated, 
promote the conversion of Gli repressor (Gli3r) forms into 
full-length activator forms. The Gli activators (Gli3a) induce the 
expression of Hh target genes cyclin D1, Gli1, Gli2, N-myc, and 
Ptch1. An intact Hh pathway is important for ciliogenesis. The 
evidence implicating the defects of the Hh signaling in NPHP, 
renal development and cystogenesis is evolving (77, 103). Loss 
of the transcription factor Glis2 (Gli-similar zinc finger protein) 
causes NPHP type 7 (56), Shh knockout mouse embryos showed 
either renal agenesis or cystic dysplasia (143) and upregulated 
Indian Hh has been implicated in cystogenesis (144). A subset 
of BBS proteins has been shown to modulate Shh signaling and 
interact with IFT proteins (145). More recently, Hh signaling has 
been shown to be dysregulated in models of cystic kidney disease 
including Thm1, Pkd1, jck (103) and Cep290 (95).
THe CiliARY TRANSiTiON ZONe  
AND liNKS TO NPHP
Between the basal body and the ciliary axoneme lies the transi-
tion zone, a physical barrier between the ciliary membrane and 
the apical plasma membrane of the cell. Several genes causing 
NPHP encode transition zone components, including NPHP1, 
RPGRIP1L, NPHP4, and CEP290. The transition zone controls 
the protein entry into and exit from the primary cilium and the 
composition of the ciliary membrane, which directly impacts cili-
ary signaling pathways such as Hedgehog signaling. The hedgehog 
signaling molecule Smoothened has been shown to accumulate 
in discrete clusters in the transition zone, and RPGRIP1L muta-
tions disrupted this localization, leading to disrupted signaling 
(146). These data support the hypothesis of the transition zone 
as a gatekeeper of the cilium and that defects can account for 
phenotypes such as NPHP.
DDR PATHwAYS AND NPHP
The DDR signaling pathway allows the cell to detect DNA 
damage, apply an arrest in cell cycle and promote repair of the 
DNA. Repair of double stranded DNA breaks is particularly 
important for the maintenance of chromosome integrity. The 
DNA damage pathway ensures that damaged cells do not pro-
gress through S phase and into mitosis before repair is complete. 
Recently, several of the proteins implicated in NPHP including 
NEK8 (99), CEP164 (147), ZNF423 (63), SDCCAG8 (58, 59), 
and CEP290 (96) have been implicated in this pathway, sug-
gesting a nuclear (non-ciliary) role. Following DNA damage, 
ZNF423, CEP164, and SDCCAG8 proteins have been shown to 
colocalize to nuclear foci positive for TIP60, a marker of sites 
of DNA damage and knockdown of CEP164 or ZNF423 causes 
increased sensitivity to DNA damaging agents (63). These 
observations provided a hypothesis that may explain why some 
NPHP genes with null mutations (such as NPHP3, CEP290, 
and RPGRIP1L) present as severe congenital-onset dysplasia 
and malformation in multiple organs including the kidney, 
brain and eye while hypomorphic mutations in the same genes 
produce milder phenotypes, which include late-onset degen-
eration and fibrosis leading to NPHP in the kidney and retinal 
degeneration in the eye. During periods of high proliferation 
and replication stress such as morphogenesis, DDR signaling is 
essential, and defects may lead to tissue dysplasia. By contrast, 
during maintenance of tissues in postnatal life, low replication 
stress would be expected, and defects would produce a degen-
erative phenotype. This hypothesis may go some way to explain 
the organ specific phenotypes seen in Joubert syndrome and 
other syndromes associated with NPHP (63). DDR defects and 
replication stress may also be an explanation for the fibrosis seen 
in association with NPHP and represents drugable target for the 
disease, which may be independent from and more reversible 
than cystogenesis (96, 148).
AN iNTeGRATiON OF SiGNAliNG 
PATHwAYS iN THe DevelOPMeNT  
OF NPHP
It remains clear that given the genetic heterogeneity of NPHP 
and the numerous mechanistic pathways discussed that there 
is not one unifying pathology leading toward NPHP. The renal 
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histology of NPHP points to a common endpoint of tubular 
damage and fibrosis, which may have multiple triggers. With each 
new gene discovery paper, there seems to be better clarity toward 
molecular diagnosis but more confusion regarding the signaling 
pathways underlying disease.
The clear themes concerning NPHP are that this disease is 
a manifestation of a renal ciliopathy with almost all NPHP-
associated genes encoding gene products known to localize 
to primary cilia and regulate ciliary function and structure 
(149), with both the Hedgehog and Wnt signaling pathways 
implicated downstream from abnormal ciliary signaling. The 
function of the ciliary transition zone as a gatekeeper for 
ciliary protein entry and exit is clearly fundamental to cili-
ary signaling processes. Protein interaction studies of NPHP 
proteins now allow the proteins to be grouped into four dis-
tinct modules. These are the NPHP1–4–8 (NPHP1, NPHP4, 
and RPGRIP1L) module, the NPHP2–3–9-ANKS6 (INVS, 
NPHP3, NEK8, and ANKS6) module, the NPHP5–6 (IQCB1 
and CEP290) module and the MKS module (MKS1, CC2D2A, 
and TCTN2). This points to the fact that each NPHP protein 
has a distinct localization and function within the centrosome/
transition zone/cilium.
However, there is also growing evidence for a nuclear/DDR 
function of some NPHP-associated proteins, which may be 
important in disease initiation and progression. Whether this 
is independent of roles in the primary cilium is not known. It 
is possible that loss of ciliary function may be a downstream 
effect of nuclear events affecting cell cycle progression as a 
result of replication stress (148). The intimate relationship 
between ciliogenesis and DDR has recently been discussed 
(150). Centrosomal proteins including NEK8 and CEP290 
that are mutated in ciliopathy disorders and are known to have 
functional roles in DDR are discussed in detail. Overall, it 
seems likely, given the body of evidence concerning cilia and 
cystic kidney disease that ciliary dysfunction is a relatively 
specific subcellular phenotype and final common pathway 
leading to NPHP, but other pathways may feed into this and 
be interrelated.
TReATMeNT OF NPHP
Nephronophthisis is incurable at present, but a range of poten-
tial therapeutic interventions has arisen from several lines of 
investigation into the pathogenesis of NPHP. Elevated renal 
cAMP levels were found associated with the cystic phenotype 
of NPHP and the modulation of cAMP production has been 
extensively explored as a potential strategy in the treatment 
of cystic kidney disease (51, 151–154). V2R antagonists are 
able to slow the rate of cAMP production by inhibiting V2R 
that, by coupling with G proteins, regulates the activity of 
adenylate cyclase and mediates urine concentration. Indeed, 
V2R antagonists OPC31260 and tolvaptan were shown to be 
effective in reducing renal accumulation of cAMP and rescuing 
the cystic kidney phenotype in Pcy mice (a model of NPHP3) 
(16, 51, 153). The use of tolvaptan has now moved successfully 
from preclinical models, through clinical trials (155) and into 
clinical practice (156). Its use in childhood ADPKD is cur-
rently being investigated in clinical trials.
As discussed, several lines of evidence support a direct link 
between DNA damage and the loss of NPHP proteins. In par-
ticular, both the NPHP type nine associated protein NEK8 and 
Cep290 were shown to be important regulators of DNA damage 
as their loss leads to increased sensitivity to replication stress and 
increased levels of CDKs (96, 99). Interestingly, CDK inhibition 
is able to suppress the DNA damage caused by loss of NEK8 or 
Cep290, therefore providing a rationale for CDK inhibition as 
a potential strategy in the treatment of NPHP (96, 99). Indeed, 
the CDK inhibitor roscovitine and its analog S-CR8 significantly 
halted the progression of cystic phenotype and attenuated loss of 
kidney function in jck mice (carrying a mutation in Nek8) (99, 
157). Furthermore, roscovitine was able to ameliorate the ciliary 
phenotype of renal epithelial cells derived from a patient with 
NPHP secondary to a mutation in CEP290. Interestingly, it was 
shown that the treatment with purmorphamine, an agonist of the 
Shh pathway, is not only as effective as roscovitine in rescuing the 
ciliary defect, but is also able to decrease CDK5 protein levels in 
patient cells, suggesting a possible convergence of these signaling 
pathways (158).
Given the pivotal role played by the primary cilium in the 
context of Hh pathway, a manipulation of Hh signaling appears 
as an appealing strategy in the treatment of ciliopathies such 
as NPHP. It has been shown that genetic deletion of Gli2 can 
ameliorate the cystic kidney phenotype in an orthologous 
mouse model of TTC21B (56), while Hh agonism mediated by 
purmorphamine treatment is able to rescue the architectural 
defect displayed by 3D cultures of CEP290 renal epithelial 
cells (95).
Hyperactivation of mTOR (mechanistic target of rapa-
mycin) pathway was found to be associated with cystic kidney 
disease and rapamycin has proven to be effective in several 
rodent [Han:SPRD rat (134, 159), LPK rat (135), Pcy mouse 
(133), and zebrafish models (invs, iqcb1, and cep290 morphant) 
of NPHP (160)].
The zebrafish models of NPHP are proving also to be extremely 
useful for high-throughput drug screens to determine their effect 
on kidney development (161).
There is hope therefore that these and other animal models 
of NPHP will provide valuable insights for future personal-
ized medicine treatments of NPHP in affected patients (162). 
However, despite the great number of promising interventions 
that has arisen from preclinical studies, no clinical trials have 
yet been conducted to test their therapeutic potential in NPHP 
patients, most of whom eligible for treatment would be less than 
18 years of age (125).
To date, options for the treatment of NPHP remain sup-
portive. Control of blood pressure is a priority in children and 
young adults affected. Management of complications arising 
from progressive renal failure such as anemia, symptoms of 
uremia and fluid overload are important alongside preparation 
for future renal replacement therapy. This disease does not recur 
in a transplant and renal transplantation remains the ideal mode 
of renal replacement therapy.
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CONClUSiON
The clinical and pathological diagnosis of NPHP is important, 
given its progression to ESRD and its associated extrarenal mani-
festations. Molecular genetic investigations allows a diagnosis in 
around one-third of cases and can give insights into the associated 
disease features, the underlying mechanisms and hopefully pave 
the way for individualized treatments for the underlying kidney 
disease. As this review demonstrates, it is true that many genes 
cause NPHP and while most of the identified molecular causes 
implicate the primary cilium in the pathogenesis of NPHP, it 
has also become apparent that there are important differences in 
the underlying pathophysiology. The traditional descriptions of 
NPHP of infantile, juvenile, and adolescent may now seem dated; 
however, they highlight the fact that different genetic forms of the 
disease disrupt the kidney by different mechanisms, demanding a 
precision medicine approach to the diagnosis, understanding and 
treatment of NPHP and its associated syndromes.
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